GMED Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the investor's beginner level, long-term strategy, and available funds, Globus Medical Inc (GMED) is a good buy. The company has strong financial performance, positive analyst sentiment, and a favorable growth trajectory. Despite minor insider selling and lack of immediate trading signals, the long-term growth potential and consistent analyst upgrades make this a solid investment for a patient, long-term investor.
The MACD is positively expanding, indicating a potential bullish trend. RSI is neutral at 45.406, and moving averages are converging, suggesting no strong directional bias. Key support is at 85.083, and resistance is at 87.94. The stock closed at 87.12, slightly above the pivot point of 86.511, indicating stability.
Strong Q4 2025 financial performance with revenue up 25.73% YoY and net income up 430.44% YoY.
Positive analyst sentiment with multiple price target upgrades and Buy/Overweight ratings.
High conviction from analysts on sustained growth in core spine and enabling technologies.
Insider selling has increased significantly by 389.20% over the last month.
No recent congress trading data or significant hedge fund activity.
Lack of immediate proprietary trading signals from AI Stock Picker or SwingMax.
In Q4 2025, Globus Medical reported revenue of $826.42M, up 25.73% YoY. Net income increased to $140.59M, up 430.44% YoY, with EPS rising to 1.03, up 442.11% YoY. Gross margin improved to 64.85%, up 17.12% YoY, showcasing robust financial health and operational efficiency.
Analysts maintain a strong positive outlook on GMED, with multiple firms raising price targets recently. Current price targets range from $104 to $123, with consistent Buy/Overweight ratings. Analysts highlight impressive Q4 results, strong growth in core spine, and potential for margin expansion.
